Research ArticleOMERACT 11
Updating the OMERACT Filter: Discrimination and Feasibility
George Wells, Dorcas E. Beaton, Peter Tugwell, Maarten Boers, John R. Kirwan, Clifton O. Bingham III, Annelies Boonen, Peter Brooks, Philip G. Conaghan, Maria-Antonietta D’Agostino, Maxime Dougados, Daniel E. Furst, Laure Gossec, Francis Guillemin, Philip Helliwell, Sarah Hewlett, Tore K. Kvien, Robert B. Landewé, Lyn March, Philip J. Mease, Mikkel Ostergaard, Lee Simon, Jasvinder A. Singh, Vibeke Strand and Désirée M. van der Heijde
The Journal of Rheumatology May 2014, 41 (5) 1005-1010; DOI: https://doi.org/10.3899/jrheum.131311
George Wells
From the Cardiovascular Research Methods Centre, Department of Epidemiology and Community Medicine, University of Ottawa; Department of Medicine, University of Ottawa, Ottawa, Ontario,
Canada; Departments of Epidemiology and Biostatistics, and Rheumatology, VU University Medical Center, Amsterdam,
The Netherlands; University of Bristol Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol,
UK; Department of Occupational Sciences and Occupational Therapy, Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario,
Canada; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland,
USA; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht University, Maastricht,
The Netherlands; Australian Health Workforce Institute (AHWI), School of Population Health, University of Melbourne, Melbourne,
Australia; Division of Musculoskeletal Disease, University of Leeds, and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds,
UK; Versailles-Saint Quentin En Yvelines University, Department of Rheumatology, Ambroise Paré Hospital, APHP, Boulogne-Billancourt; Paris-Descartes University, Medicine Faculty, APHP, Cochin Hospital, Rheumatology B, Paris,
France; Section of Rheumatology, Cardiff University School of Medicine, Cardiff,
UK; Department of Rheumatology, Geffen School of Medicine at the University of California in Los Angeles; Los Angeles, California,
USA; Université Pierre et Marie Curie (UPMC) - Paris 6, GRC-UMPC 08 (EEMOIS); AP-HP Pitié Salpêtrière Hospital, Department of Rheumatology, Paris; Université de Lorraine, Université Paris Descartes, Nancy,
France; University of Leeds, Section of Musculoskeletal Disease, LIMM Chapel Allerton Hospital, Leeds West Yorkshire; University of the West of England, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol,
UK; Department of Rheumatology, Diakonhjemmet Hospital, Oslo,
Norway; Department of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center Heerlen,
The Netherlands; Institute of Bone and Joint Research, Sydney Medical School and School of Public Health, University of Sydney, Sydney; Department of Rheumatology, Royal North Shore, St. Leonards, New South Wales,
Australia; Seattle Rheumatology Associates, Swedish Medical Center Rheumatology Research Division, University of Washington School of Medicine, Seattle, Washington,
USA; Department of Rheumatology, Copenhagen University Hospital at Glostrup, Copenhagen,
Denmark; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, University of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, Alabama; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California,
USA; Department of Rheumatology, Leiden University Medical Center, Leiden,
The Netherlands.
Dorcas E. Beaton
Peter Tugwell
Maarten Boers
John R. Kirwan
Clifton O. Bingham III
Annelies Boonen
Peter Brooks
Philip G. Conaghan
Maria-Antonietta D’Agostino
Maxime Dougados
Daniel E. Furst
Laure Gossec
Francis Guillemin
Philip Helliwell
Sarah Hewlett
Tore K. Kvien
Robert B. Landewé
Lyn March
Philip J. Mease
Mikkel Ostergaard
Lee Simon
Jasvinder A. Singh
Vibeke Strand
Désirée M. van der Heijde
Abstract
The “Discrimination” part of the OMERACT Filter asks whether a measure discriminates between situations that are of interest. “Feasibility” in the OMERACT Filter encompasses the practical considerations of using an instrument, including its ease of use, time to complete, monetary costs, and interpretability of the question(s) included in the instrument. Both the Discrimination and Reliability parts of the filter have been helpful but were agreed on primarily by consensus of OMERACT participants rather than through explicit evidence-based guidelines. In Filter 2.0 we wanted to improve this definition and provide specific guidance and advice to participants.
In this issue
The Journal of Rheumatology
Vol. 41, Issue 5
1 May 2014
Updating the OMERACT Filter: Discrimination and Feasibility
George Wells, Dorcas E. Beaton, Peter Tugwell, Maarten Boers, John R. Kirwan, Clifton O. Bingham, Annelies Boonen, Peter Brooks, Philip G. Conaghan, Maria-Antonietta D’Agostino, Maxime Dougados, Daniel E. Furst, Laure Gossec, Francis Guillemin, Philip Helliwell, Sarah Hewlett, Tore K. Kvien, Robert B. Landewé, Lyn March, Philip J. Mease, Mikkel Ostergaard, Lee Simon, Jasvinder A. Singh, Vibeke Strand, Désirée M. van der Heijde
The Journal of Rheumatology May 2014, 41 (5) 1005-1010; DOI: 10.3899/jrheum.131311
Updating the OMERACT Filter: Discrimination and Feasibility
George Wells, Dorcas E. Beaton, Peter Tugwell, Maarten Boers, John R. Kirwan, Clifton O. Bingham, Annelies Boonen, Peter Brooks, Philip G. Conaghan, Maria-Antonietta D’Agostino, Maxime Dougados, Daniel E. Furst, Laure Gossec, Francis Guillemin, Philip Helliwell, Sarah Hewlett, Tore K. Kvien, Robert B. Landewé, Lyn March, Philip J. Mease, Mikkel Ostergaard, Lee Simon, Jasvinder A. Singh, Vibeke Strand, Désirée M. van der Heijde
The Journal of Rheumatology May 2014, 41 (5) 1005-1010; DOI: 10.3899/jrheum.131311